✦ LIBER ✦

Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies

✍ Scribed by Stefan Vitko; Helio Tedesco; Josette Eris; Julio Pascual; John Whelchel; John C. Magee; Scott Campbell; Giovanni Civati; Bernard Bourbigot; Gentil Alves Filho; John Leone; Valter Duro Garcia; Paolo Rigotti; Ronaldo Esmeraldo; Vincenzo Cambi; Tomas Haas; Annette Jappe; Peter Bernhardt; Johanna Geissler; Nathalie Cretin

Book ID: 114803073
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 115 KB
Volume: 4
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2004.00389.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

12-month safety and efficacy of everolim

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

Efficacy and safety of tacrolimus versus

Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan

✍ C.H. Wang; W.J. Ko; N.K. Chou; S.S. Wang 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Efficacy and safety of tacrolimus (TAC)

Efficacy and safety of tacrolimus (TAC) vs. cyclosporine microemulsion (CME) in de novo cardiac transplant recipients: 6-month results

✍ M Grimm; M Rinaldi; N.A Yonan 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Prospective Clinical Trial Comparing Two

Prospective Clinical Trial Comparing Two Immunosuppressive Regimens, Tacrolimus and Mycophenolate Mofetil Versus Everolimus and Low-Dose Cyclosporine, in De Novo Renal Transplant Recipients: Results at 6 Months Follow-up

✍ E. Favi; F. Citterio; G. Spagnoletti; A. Gargiulo; F. Delreno; J. Romagnoli; M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 113 KB

15: Results of a 12-Month, Multicenter,

15: Results of a 12-Month, Multicenter, Randomized Trial of Everolimus with Reduced-Exposure Cyclosporine Versus MMF and Standard-Exposure Cyclosporine in De Novo Cardiac Transplant Recipients

✍ H. Lehmkuhl; U. Livi; J. Arizon; M. Viganò; C. Magelli; P. Boissonnat; G. Gerosa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Efficacy and safety of de novo or early

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB